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Abstract
Background: Sinonasal adenocarcinomas are uncommon tumors which develop in the ethmoid sinus
after exposure to wood dust. Although the etiology of these tumors is well defined, very little is known
about their molecular basis and no diagnostic tool exists for their early detection in high-risk workers.
Methods: To identify genes involved in this disease, we performed gene expression profiling using cancer-
dedicated microarrays, on nine matched samples of sinonasal adenocarcinomas and non-tumor sinusal
tissue. Microarray results were validated by quantitative RT-PCR and immunohistochemistry on two
additional sets of tumors.
Results: Among the genes with significant differential expression we selected LGALS4, ACS5, CLU, SRI and
CCT5 for further exploration. The overexpression of LGALS4, ACS5, SRI, CCT5 and the downregulation of
CLU were confirmed by quantitative RT-PCR. Immunohistochemistry was performed for LGALS4
(Galectin 4), ACS5 (Acyl-CoA synthetase) and CLU (Clusterin) proteins: LGALS4 was highly up-regulated,
particularly in the most differentiated tumors, while CLU was lost in all tumors. The expression of ACS5,
was more heterogeneous and no correlation was observed with the tumor type.
Conclusion: Within our microarray study in sinonasal adenocarcinoma we identified two proteins,
LGALS4 and CLU, that were significantly differentially expressed in tumors compared to normal tissue. A
further evaluation on a new set of tissues, including precancerous stages and low grade tumors, is
necessary to evaluate the possibility of using them as diagnostic markers.
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Sinonasal adenocarcinoma is a rare cancer which usually
develops in the ethmoid sinuses. It mainly develops
amongst 30 to 85 year old men, with a high frequency
around 60. The incidence of this type of cancer was esti-
mated by the IARC (International Agency for Research on
Cancer) at 0.7/100 000 in China to 1.4/100 000 in USA
and 1.5/100 000 in France, and it has been reported to
account for 3% of head and neck tumors [1,2]. This cancer
is recognized as an occupational cancer. In fact, it is well
confirmed today that sinonasal adenocarcinoma is highly
correlated with duration and level (3.5 mg/m3) of wood
dust exposure [3,4]. As such, woodworkers have very high
risks of nasal cancer (Standard Mortality Ratio: 310, 95%
CI, 160-560) [5,6]. Other suspected risk factors include
exposure to leather dust [7,8], metals such as chromium
or nickel [9,10], and formaldehyde, although the epide-
miological data regarding this chemical are partly conflict-
ing [4,11]. In contrast to most other head and neck
cancers, alcohol and tobacco do not seem to be risk fac-
tors [12]. Although the etiology of sinonasal adenocarci-
noma is well-defined, its wood-related pathogenesis is not
clearly understood [13]. From a morphological and his-
topathological point of view, these tumors are mainly
intestinal-type adenocarcinomas [14,15] and demon-
strate characteristic changes, such as gland formation,
seen in adenocarcinomas at other anatomic sites. The
most common clinical symptoms (nosebleeding, rhinitis
and nasal obstruction) are not specific and this explains
the delay in the diagnosis and the frequency of advanced
stages. The conventional treatment includes local surgery
[16] associated with radiotherapy. The survival rate at 5
years is only about 50% and it is important to point out
that secondary effects are considerable due to the location
of these tumors [17]. Therefore, early detection and alter-
native treatments are necessary. This requires, however,
better knowledge of the molecular mechanisms involved
in the development of these tumors. Although many
reports on epidemiological studies and risk factors of
sinonasal adenocarcinomas have been published, only a
small number of reports have been made so far on their
molecular biology. As reviewed recently by Llorente et al
[13], several groups have proceeded with molecular stud-
ies of sinonasal adenocarcinomas. However these focused
on specific genes, such as ERBB1, CCND1, ERBB2, TP53,
K-ras, COX-2 or APC, involved either in other head and
neck tumors or in colorectal cancer because of morpho-
logical similarities [13,18,19]. Two groups reported com-
parative genomic hybridization in ethmoid sinus
adenocarcinomas and revealed hot spots of chromosomal
imbalances [20-22]. Global genetic modifications (micro-
nuclei and chromosomal aberrations) were also found in
buccal epithelial cells and blood lymphocytes of wood
furniture workers [23]. The conclusion of all these investi-
gations is that ethmoid sinus adenocarcinomas have their
own molecular development pathway.
Thus, to identify genes involved in this pathway, we pio-
neered a gene expression profiling study of 9 sinonasal
adenocarcinomas versus their matched normal tissue. We
found 186 genes with significant differential expression.
The further evaluation of several selected genes by reverse-
transcription quantitative real-time-PCR (RT-qPCR) and
immunohistochemistry (IHC), on two additional valida-
tion samples, confirmed the microarray data. We have
hereby opened up a new field of investigation into
biomarkers of this tumor type and have identified two
promising candidate genes: LGALS4 and CLU.
Methods
Subjects
Our study included 26 patients. A first set of 19 male
patients undergoing surgery for ethmoid sinus adenocar-
cinomas were initially included between 2004 and 2006.
Following this, a second set of 7 patients whose samples
were collected from 2006 to 2007 was used to complete
the immunohistochemistry study.
This project was approved by the Clinical Board of the
Centre Hospitalo-Universitaire of Nantes and all included
patients provided written informed consent in accordance
with French regulations and the Declaration of Helsinki.
All patients answered a codified questionnaire regarding
occupational exposures, addictive consumption and fam-
ily history. Twenty three patients out of 26 were exposed
to wood dust and most of them had other occupational
exposures (such as solvents and pesticides) sometimes
combined with tobacco and/or alcohol. Two patients
were exposed to leather dust (P7, P19), whereas only one
(P10) had no occupational exposure (Table 1). Patient
ages ranged from 50 to 80 years with a mean age of 69
years. To date, six patients have died as a direct result of
their disease (Table 1).
Tissue specimens
Two pieces of tissue samples were obtained from each
patient undergoing surgery for ethmoidal adenocarci-
noma: one from the tumor and one non-tumor sample
obtained from the opposite sinus at 3 to 4 cm distance
(herein referred to as "normal" tissue). All samples were
immediately frozen and stored at -80°C. Remaining sur-
gical resections of tumors and normal tissue were fixed in
10% formalin and embedded in paraffin before histolog-
ical examination and diagnosis according to World
Health Organization recommendations [24]. Two main
types of sinonasal adenocarcinoma are recognized in the
ethmoid sinus based on the histological similarity to ade-
nocarcinoma of the intestine: Intestinal Type Adenocarci-
noma (ITAC) and non-Intestinal Type AdenocarcinomaPage 2 of 12
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ries [15,25]: the "papillary-type" (well-differentiated ade-
nocarcinoma), the "colonic-type" (moderately-
differentiated adenocarcinoma), the "solid-type" (poorly-
differentiated adenocarcinoma), the "mucinous--type"
and the "mixed--type" composed of a mixture of the pre-
viously defined patterns. Non-ITAC are divided into low-
grade and high-grade subtypes.
RNA extraction
On each matched normal and pathological tissue speci-
men from patients P1 to P19, two RNA extractions were
performed from about 40 frozen sections (10 μm thick)
using a Total RNA and Protein Isolation kit (Macherey-
Nagel, Düren, Germany) according to the manufacturer's
instructions. For each sample, the first and last sections
were stained with hemalun/phloxin to confirm the histol-
ogy and to evaluate the percentage of tumor tissue. 10
samples had to be eliminated for microarray analysis
because of necrosis or a too low percentage of non-
necrotic tumor tissue (less than 50%). Six out of these ten
patients were included in the validation process by RT-
qPCR as this technique is more sensitive than microarrays
for identifying tumor cells within a sample. The other
samples were completely excluded from the molecular
analysis (Table 1).
The quantity and quality of each RNA were respectively
evaluated with the NanoDrop® ND-1000 spectrophotom-
eter (Nanodrop Technologies, Wilmington, DE) and the
Agilent 2100 Bioanalyser (Agilent, Santa Clara, CA). The
RNAs extracted were of good quality and the RNA integ-
rity number (RIN) was >7.5 in all cases [26].
RNA amplification and microarray hybridization
Cancer-dedicated microarrays were prepared in-house
(ADN-OGP- Microarray Platform Nantes, France) with
methods previously described in detail [27,28] using
22,175 probe sets (50-mer oligonucleotides - MWG Bio-
tech, Roissy, France) interrogating 6,864 genes involved in
Table 1: Summary of clinical data and use of tumor samples
Patient Age Dust
exposurea (years)
Tobacco/alcohol Otherb TNM stage
UICC2003[61]
Treatmentd Outcomee Micro-array q RT PCR IHC
1 69 W (42) + + T2N0 M0 S, R A - + +
2 79 W (45) - - R4bN0 M0C S, R DOD - - +
3 72 W (25) + + R3N0 M0 S, R A - - +
4 55 W (17) + + T3N0 M0 S, R A - + +
5 62 W (3) - + T4bN0 M0 S DOD + + +
6 71 W (37) + + R3N0 M0 S, R A + + +
7 83 L (5) + + T4aN0 M0 S, R DOD - - +
8 66 W (43) - - T4bN0 M0 S DOD + + +
9 76 W (27) + + R3N0 M0 S, R A + + +
10 50 - + - T4aN0 M0 S, R A + + +
11 75 W (43) - + T3N0 M0 S, R A - + +
12 81 W (41) - + T4aN0 M0 S, R DOD + + +
13 71 W (30) - + T3N0 M0 S, R A - + +
14 60 W (25) + + T2N0 M0 S, R A + + +
15 73 W (6) + - T2N0 M0 S, R A - - +
16 68 W (32) + - T2N0 M0 S, R A + + +
17 70 W (25) - - T2N0 M0 S, R A - + +
18 79 W (20) - - T2N0 M0 S, R D - + +
19 77 L (12) + + T4aN0 M0 S, R A + + +
20 65 W (35) - + T2N0 M0 S, R A - - +
21 90 W (30) + - T3N0 M0 S, R A - - +
22 54 W (42) - - T2N0 M0 S, R A - - +
23 68 W (31) + + T3N0 M0 S, R A - - +
24 71 W (41) + + T2N0 M0 S, R A - - +
25 73 W (30) - + T4aN0 M0 S, R A - - +
26 75 W (9) - + T4bN0 M0 S, R DOD - - +
a: dust exposure: W = wood, L = leather
b: pesticides (xylophene), solvents (acetone, formaldehyde)
c: R = recurrent tumor
d: treatment: S = surgery, R = radiotherapy post-surgery
e: DOD = death from the disease, D = death from other causes, A = alivePage 3 of 12
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included triplicate probes for each gene, housekeeping
genes and controls.
For microarray analysis one round of amplification was
conducted on 500 ng total RNA using an Amino Allyl
MessageAmp®II aRNA Amplification kit (Ambion, Austin,
TX) according to the manufacturer's instructions, and the
quantity and quality of each amplified RNA (aRNA) were
again evaluated. Microarrays were carried out in duplicate
for both RNA extractions of each tissue except for two
patients as not enough RNA was available. The targets
were prepared by labeling with Cy3-dUTP aRNA from the
tumor and normal tissues. In order to reduce individual
variations, the reference was prepared by mixing an equal
quantity of all normal tissues [29,30] and aliquots were
then labeled with Cy5-dUTP (Amersham Biosciences, Pis-
cataway, NJ). Each Cy3-dUTP sample was mixed with an
equal amount of Cy5-dUTP reference sample and the mix-
ture was applied to microarray slides for hybridization at
40°C for 16 h [27]. The slides were then washed twice at
room temperature for 2 min with 2× SSC and 0.1% SDS,
for 2 min with 1× SSC, and twice for 2 min with 0.2× SSC
and scanned at 10 μm/pixel resolution by ScanAr-
ray®ExpressHT (PerkinElmer Life Sciences, Boston, MA).
Microarray data analysis
Scanned signals were quantified from all microarrays by
GenePix Pro software version 5.1 (Axon Instruments,
Union City, CA) and consolidated expression values were
performed by MADSCAN software in five steps [30,31].
The information was extracted from the features close to
the background or saturated and normalization was per-
formed by the rank invariant and lowest fitness method
with spatial normalization. Outlier values were elimi-
nated with the spots in triplicate and biological replicates.
To identify genes differentially expressed in tumor sam-
ples, a two-class comparison analysis by Significance
Analysis of MicroArray (SAM) [32] was performed on data
filtered by differences between normal and pathological
tissue medians as previously described [30] and genes
with differential expression were visualized using Cluster
[33] and Tree view [31]. An unsupervised clustering was
also performed with a hierarchical clustering algorithm
[33] using the Pearson coefficient and Student test. The
clusters of genes with the same regulation were function-
ally annotated by GoMiner [34].
The data have been incorporated into the NCBI Gene
Expression Omnibus (GEO) http://
www.ncbi.nlm.nih.gov/projects/geo/ and are accessible
through GEO Series GPL 8957 and GSE 17433.
cDNA synthesis and real-time PCR (RT-qPCR)
To confirm the microarray data we performed quantita-
tive RT-PCR on selected genes using the MX4000 system
and the Brilliant SYBR Green QPCR Core Reagent Kit
(Stratagene, La Jolla, CA). Initially, cDNA was prepared in
20 μl using 1 μg of DNase-treated total RNA and the
SuperScript III Reverse Transcriptase System (Invitrogen,
Carlsbad, CA). Following a 5 fold dilution, 2 μl of each
sample were used for RT-qPCR with the different pairs of
primers (Additional file 1: "Primers sequences"). The fol-
lowing PCR cycle parameters were used: hot-start DNA
polymerase activation 95°C for 10 min, 40 cycles with
denaturation at 95°C for 30 sec, specific annealing tem-
perature as indicated in "Additional file 1: Primer
sequences" for 30 sec and extension at 72°C for 30 sec.
Each reaction was run in duplicate. The threshold cycles,
obtained from the MX4000 software, were averaged
(SD<0.5). Relative expression of the target gene in the
tumor versus matched normal tissue was calculated using
the following equation described by Pfaffl [35], using the
average Ct of three housekeeping genes: RPLPO (Ribos-
omal Protein, Large, PO), UBC (Ubiquitin C) and β2M
(beta-2 microglobulin):
Relative expression per patient and per gene:
GOI = gene of interest
HK = housekeeping gene (average of Ct of the three
housekeeping genes).
Eff = efficiency of the RT-qPCR obtained from the stand-
ard curve
Statistical significance was obtained using a pair-wise
fixed reallocation randomization test using the REST soft-
ware [36]. To insure specificity of the RT-qPCR, an agarose
gel electrophoresis was initially performed to verify
whether a single PCR product was generated and then a
melting curve was performed at the end of each RT-qPCR.
Linearity and efficiency of the RT-qPCR were checked for
each gene with a standard curve of 4 logs prepared with
Universal RNA (Stratagene-AGILENT, CA). Efficiency was
>90% in all cases.
Immunohistochemical analysis
Protein expression of selected genes was assessed in depar-
affinized 5-μm sections of normal and pathological for-
malin-fixed tissue from 26 patients with sinonasal
adenocarcinomas included in the study. The following
antibodies were used: monoclonal antibody against
human Clusterin (clone CLI-9, Alexis Corporation
R
Eff GOI Ct Normal tissue - Ct tumoral tissue GOI
Eff HK
=
^( )
 Ct normal tissue - Ct tumoral tissue HK^( )Page 4 of 12
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body against human Acyl CoA synthetase 5 (ACS5)
(Abnova, Jhongli City, Taiwan 1:200 dilution at 4°C over-
night), polyclonal antibody against Galectin-4 (T-20)
(Santa Cruz, Heidelberg, Germany, 1:50 dilution). All
specimens were submitted to heat-induced antigen
retrieval and processed using the EnVision Detection Kit
(DAKOCYTOMATION, Trappes, France), except for
LGALS4 that was processed using ABC VECTASTAIN Elite
ABC Kit (Burlingame, CA), with 3,3'-diaminobenzidine as
chromatogen and a hematoxylin counterstain. In each
experiment, negative controls were performed by omit-
ting the primary antibody.
Results
Microarray analysis
Gene expression profiles of 9 ethmoid adenocarcinomas
were examined using microarrays consisting of 6864
human genes involved in many types of cancers.
With the two-class comparison SAM, 186 genes were
found to be significantly differentially expressed between
ethmoid adenocarcinomas and normal sinonasal tissue.
Among these 186 genes, 150 were up-regulated and 36
were down-regulated (Figure 1A and "Additional File 2:
Genes with significant differential expression"). The top
59 genes (1< fold change < -1) are described in Table 2.
The genes with the highest fold expression variation were
selected for validation by RT-qPCR: LGALS4 (fold change:
3.6), ACS5 (fold change: 2.1), and CLU (fold change: -
3.6). By unsupervised clustering (i.e. without any initial
classification of the samples) 7 tumors out of 9 were sep-
arated from normal samples (Figure 1B). However, 5 clus-
ters of genes with differential expression between tumor
and normal samples were revealed. Using GoMiner [34]
the genes involved in metabolism and biosynthesis func-
tions were found to be overexpressed, whereas those
involved in transcription, angiogenesis, cellular signaling
and mitochondrial functions were down-regulated. Based
on this non-supervised analysis 2 more genes with high
differential expression were selected for RT-qPCR analysis:
SRI and CCT5. Involved in drug resistance, these genes
also featured in the list of overexpressed genes obtained
from the two-class comparison analysis, with a fold
change of 1.5 and 0.9 respectively.
Relative expression level of selected genes
To validate the differential gene expression obtained by
microarray analysis, quantitative PCR analysis of the
selected genes was performed in matched sets of tumors
and normal tissues. The patients used for microarray anal-
ysis and 6 additional patients were included. As RNA from
normal tissue was no longer available, we used the Ct
average (SD<1Ct) of all normal tissues for P8 and P19
patients to calculate the relative expression level of each
gene [35].
A significant differential expression in tumor tissue versus
normal tissue was confirmed for all selected genes. The
genes with the highest overexpression were LGALS4 with
a mean ratio of 1309 (0.17-5993, p = 0.001), then ACS5
with a mean ratio of 9.48 (0.14-23.55, p = 0.001). P10
and P11 patients overexpressed neither LGALS4 nor
ACS5. (Figure 2A-B). CLU was highly down-regulated in
most of the tumors (mean ratio:0.044, 0.005-0.26, p =
0.001) (Figure 2C). Many isoforms of CLU have been
described in the literature [37], and we quantified by RT-
qPCR the main ones, i.e. the nuclear form (n-clu) and the
cytosolic form (s-clu). Both were found to be down-regu-
lated (data not shown). Regarding SRI and CCT5, their sig-
nificant up regulation was confirmed (p = 0.0016 and p =
0.006 respectively) although the fold change was much
lower ("Additional file 3: Relative expression of SRI and
CCT5").
Immunohistochemical analysis of LGALS4, ACS5 and CLU
To confirm the variation in expression of the selected
genes at the protein level, we performed immunohisto-
chemical analysis of matched normal sinonasal and
tumor tissues from the 15 patients used for the molecular
analysis as well as from an independent set of 11 other
patients, using specific antibodies for LGALS4, ACS5 and
CLU (Table 3). In the normal sinusal mucosa, these three
markers were expressed by serous cells of the seromuci-
nous glands present in the lamina propria. A weak and
focal cytoplasmic staining of a small number of seromuci-
nous glands was observed with the antibodies against
LGALS4 and CLU while the staining was more intense and
diffuse for ACS5 (Figure 3A-B-C). Among the 26 tumors
analyzed, only 2 were high-grade non-ITAC and the oth-
ers were ITAC: 5 "papillary-type" (well-differentiated ade-
nocarcinoma), 2 "colonic-type" (moderately-
differentiated adenocarcinoma), 9 "mucinous-type" ade-
nocarcinoma and 8 mixed-type adenocarcinoma (Table
3).
With the LGALS4 antibody the ITAC tumor cells displayed
a strong cytoplasmic and membranous staining with an
additional nuclear staining in the well-differentiated ade-
nocarcinomas. Interestingly, in a mixed ITAC sample (P5)
the poorly differentiated "solid-type" component showed
no immunoreactivity for LGALS4 while the "colonic-type"
component was positive (Table 3 and Figure 3D). Non-
ITAC samples displayed no LGALS4 expression.
For ACS5, fifty percent of the tumor samples were negative
while the remaining 50% showed a weak to strong cyto-
plasmic staining without any correlation with the histo-Page 5 of 12
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Accession
Number
Gene Symbol Gene annotation Fold change (log2)
NM_006149 LGALS4 Up-regulated genes
lectin, galactoside-binding, soluble, 4 (galectin 4)
3.084
NM_016234 ACS5 fatty-acid-Coenzyme A ligase, long-chain 5 2.621
NM_001845 COL4A1 collagen, type IV, alpha 1 1.779
NM_002228 JUN v-jun sarcoma virus 17 oncogene homolog (avian) 1.758
NM_001816 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 1.732
NM_001122 ADFP adipose differentiation-related protein 1.628
XM_067746 similar to 60 kDa heat shock protein, mitochondrialprecursor (Hsp60) (60 kDa 
chaperonin) (CPN60) (Heat shock protein60) (HSP-60)
1.617
NM_004591 CCL20 chemokine (C-C motif) ligand 20 1.560
BC000097 TGFBI transforming growth factor, beta-induced, 68 kDa 1.493
NM_000393 COL5A2 collagen, type V, alpha 2 1.461
NM_003130 SRI sorcin 1.456
NM_001153 ANXA4 annexin A4 1.434
NM_005566 LDHA lactate dehydrogenase A 1.416
NM_005563 STMN1 stathmin 1/oncoprotein 18 1.414
NM_017958 PLEKHB2 pleckstrin homology domain containing, family B (evectins) member 2 1.409
XM_092196 similar to Cytochrome c, somatic (LOC164837), mRNA. 1.387
AF112214 MRPL13 mitochondrial ribosomal protein L13 1.370
AJ250915 HSPD1 heat shock 60 kDa protein 1 (chaperonin) 1.346
BC003623 YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
polypeptide
1.342
NM_006111 ACAA2 acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 1.335
NM_021821 MRPS35 mitochondrial ribosomal protein S35 1.329
NM_002592 PCNA proliferating cell nuclear antigen 1.319
NM_001827 CKS2 CDC28 protein kinase regulatory subunit 2 1.278
AB062125 TPM3 tropomyosin 3 1.224
NM_016245 DHRS8 dehydrogenase/reductase (SDR family) member 8 1.206
NM_001226 CASP6 caspase 6, apoptosis-related cysteine protease 1.194
NM_004670 PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.172
XM_088293 similar to cytochrome c (LOC157317), mRNA. 1.164
NM_001428 ENO1 enolase 1, (alpha) 1.145
XM_060849 similar to cytochrome C, expressed in somatic tissues(LOC128146), mRNA. 1.133
AF135381 CKLF chemokine-like factor 1.133
X84907 ENO1 enolase 1, (alpha) 1.121
NM_005720 ARPC1B actin related protein 2/3 complex, subunit 1B, 41 kDa 1.114
NM_021130 PPIA peptidylprolyl isomerase A (cyclophilin A) 1.110
NM_001288 CLIC1 chloride intracellular channel 1 1.095
BC015130 CYCS cytochrome c, somatic 1.081
NM_012255 XRN2 5'-3' exoribonuclease 2 1.068
M34664 HSPD1 heat shock 60 kDa protein 1 (chaperonin) 1.066
AF054185 PSMA7 proteasome (prosome, macropain) subunit, alpha type, 7 1.044
NM_006601 TEBP unactive progesterone receptor, 23 kD 1.037
AF136630 CBX3 chromobox homolog 3 (HP1 gamma homolog, Drosophila) 1.023
AF274941 CKS1B CDC28 protein kinase regulatory subunit 1B 1.013
AF320053 MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 1.006
Down-regulated genes
NM_001831 CLU clusterin 
(complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed 
prostate message 2, apolipoprotein J)
-3.606
NM_005978 S100A2 S100 calcium binding protein A2 -2.152
S68290 AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-
alpha)-hydroxysteroid dehydrogenase)
-2.102
NM_003713 PPAP2B phosphatidic acid phosphatase type 2B -1.966
AB000889 PPAP2B phosphatidic acid phosphatase type 2B -1.936
NM_001321 CSRP2 cysteine and glycine-rich protein 2 -1.916
NM_006485
/
FBLN1 fibulin 1 -1.799
AF007162 CRYAB crystallin, alpha B -1.590
NM_002825 PTN pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) -1.405Page 6 of 12
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3 and Figure 3E).
In contrast to normal mucosa, CLU was found to be
absent in tumors except in one high-grade non-ITAC
tumor (Patient P11) where there was a diffuse cytoplas-
mic staining (Table 3 and Figure 3F).
NM_001063 TF transferrin -1.256
NM_004186 SEMA3F sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F -1.246
NM_000424 KRT5 keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types) -1.207
AF059617 PLK2 polo-like kinase 2 (Drosophila) -1.186
NM_005596 NFIB nuclear factor I/B -1.149
NM_006206 PDGFRA platelet-derived growth factor receptor, alpha polypeptide -1.090
NM_005900 MADH1 MAD, mothers against decapentaplegic homolog 1 (Drosophila) -1.047
Table 2: Top 59 genes differentially expressed in sinonasal adenocarcinomas after two-class comparison analysis (Continued)
Heat map of the two-class comparison (A) and unsupervised (B) analysisFigure 1
Heat map of the two-class comparison (A) and unsupervised (B) analysis. Expression levels are color coded with 
red, green, black and gray, corresponding to an increase, decrease or no change in gene expression, or missing data, respec-
tively.Page 7 of 12
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Ethmoid carcinomas are uncommon tumors recognized
as an occupational disease amongst woodworkers. Cur-
rent treatment with surgery and radiotherapy is unsatisfac-
tory given the 50% survival at 5 years and the serious side
effects. To better understand the molecular events
involved in this tumor and to identify potentially novel
markers we pioneered a gene expression profiling study of
9 sinonasal adenocarcinomas.
This study, using dedicated-microarrays containing 6864
genes previously known to be involved in cancer, allowed
us to select 5 genes (LGALS4, ACS5, CLU, SRI and CCT5)
with significant differential expression between tumors
and normal tissue. We confirmed by RT-qPCR the overex-
pression of LGALS4, ACS5, SRI, CCT5 and the down-reg-
ulation of CLU. By IHC on an independent set of patients,
we focused our interest on the genes with the highest dif-
ferential expression i.e. LGALS4, ACS5 and CLU, and con-
firmed the results at the protein level for LGALS4 and
CLU.
The LGALS4 gene codes for the Galectin 4 protein [38].
Galectins constitute a family of proteins containing carbo-
hydrate recognition domains (CRD) with high affinity for
β galactosides. Their complete physiological functions are
not known but they have been reported to be involved in
inflammation, apoptosis, cell adhesion and cell growth.
LGALS4 in particular has been detected in normal epithe-
lial cells of the oral esophagus, and in the intestinal
mucosa [39,40]. In tumors, LGALS4 expression increases
in liver, gastric, breast cancer and mucinous epithelial
ovarian cancer whereas it is down-regulated in colon ade-
nocarcinoma [41-43]. The presence of two binding sites
for c-Rel, a subunit of NFκ-B, and the experimental data
obtained with transgenic mice for c-Rel, suggest that
LGALS4 could be a downstream component of the NFκ-B
pathway, known to be involved in the regulation of
tumorogenesis [44,45]. In cancer cell lines LGALS4 is
expressed in highly differentiated cell lines which form
polarized monolayers while undifferentiated cell lines do
not express LGALS4 but Galectin1 [38,42]. In our series of
ethmoid adenocarcinoma, the LGALS4 is the gene with
the highest differential expression and our IHC data are in
accordance with the literature, given that we found that
LGALS4 is overexpressed in all ethmoid tumors except the
high-grade non ITAC tumors which are poorly differenti-
ated. LGALS4 expression seems to be correlated to both
histological type and the differentiation status of the ade-
nocarcinoma. This trend was confirmed by the P5 case
where LGALS4 was overexpressed only in the "colonic-
type" component and not in the poorly differentiated
"solid-type" component of the tumor. For patient 6 (P6)
we observed a strong overexpression of LGALS4 by IHC,
which contrasts with the relative expression obtained by
RT-qPCR (fold change 0.45). We therefore hypothesize
that, in this "mucinous-type" ITAC containing numerous
mucin lakes, the RNA extracted from the tissue was not
representative of the tumor.
The highly conserved gene CLU (apolipoproteinJ, sulfated
glycoprotein 2), codes for Clusterin, a sulfated glycopro-
tein with chaperone activity found in numerous tissues
and body fluids. CLU has been reported as being involved
in many biological functions such as DNA repair, cell
cycle regulation and apoptosis [37,46]. CLU is described
as being overexpressed in several types of cancers includ-
ing colon, breast and lung cancer [37], yet a down-regula-
tion has been found in esophageal squamous cell
carcinoma, in some pancreatic, prostate or colon cancers
and in HPV-negative squamous cell carcinoma of the
head and neck [37,46,47], suggesting a pro-survival or a
pro-apoptotic function. The recent description of several
isoforms, including the nuclear form (n-CLU) and the
cytoplasmic or secreted form (s-CLU), might help to
resolve these apparent contradictions and to define the
Relative expression levels of LGALS4, ACS5, CLU, in tumors versus match d normal sinusal tissue as determined by RT-qPCRFigure 2
Relative expression levels of LGALS4, ACS5, CLU, in 
tumors versus matched normal sinusal tissue as 
determined by RT-qPCR. Fold change was calculated 
according to the equation described in the Materials and 
Methods with normalization against the average of three 
housekeeping genes, RPLPO, β2 microglobulin, and ubiquitin C. 
*tumor tissue versus average of all normal sinusal tissues (cf. 
RT-qPCR Results for details).
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as a biomarker [48-50].
In our series of ethmoid tumors, CLU was highly down-
regulated at the RNA level. Although the level of Clusterin
detected by IHC in normal tissue was rather low, we con-
firmed the down-regulation of the protein except in one
case (P11). This patient was also the one whose tumor
sample showed the least down-regulation of CLU by RT-
qPCR. This case is of interest because the patient was
exposed to wood and, in contrast with most of the cases
reported in the literature, he presented a non-ITAC tumor.
The absence of Clusterin in ethmoid tumors suggests a
pro-apoptotic function in normal ethmoidal tissue, possi-
bly in response to DNA damage caused by wood dust, or
other occupational exposures. It is useful to note that CLU
is localized on chromosome 8p21-p12 [51]. In fact, by
comparative genomic hybridization, Ariza et al. found
losses on 8p21 in about 50% of patients with sinonasal
adenocarcinomas [20]. This feature was confirmed by the
study of Korinth et al. who reported a loss of 8p in 61% of
cases [21] in a series of 42 patients. We do not know the
cytogenetics of our tumors but it would be worthwhile
ascertaining whether the down-regulation of CLU in the
tumors studied here is due to deletion on chromosome 8p
or if other mechanisms such as epigenetic regulation
occur on the CLU gene.
ACS5, Acyl coenzyme A synthetase 5 (FACL5, E.C.
6.2.1.3.), is one isoform of the ACSs, key proteins in lipid
metabolism via the activation of fatty acids in acylCoA
thioesters. These esters are the metabolites for oxidation,
elongation and desaturation of fatty acids as well as for
the synthesis of complex lipids. ACS5 is essential for lipid
metabolism but it might also play a role in intermediate
metabolism and regulation of gene expression [52]. This
gene has been well characterized in the small intestine
mucosa by Gassler et al [53,54]. ACS5 is expressed in the
enterocytes from the villus tip but not in the crypts and it
could be involved in the differentiation and maintenance
of crypt-villus axis, by inducing TRAIL apoptosis in apical
villi of the mucosa. Within the context of tumorogenesis,
Table 3: LGALS4, ACS5 and CLU expression in 26 sinonasal adenocarcinomas (IHC analysis).
Patient Tumor subtypes (Barnes'classification [25]) CLUa ACS5 LGALS4
1 ITAC mixed (papillary and mucinous) - - +++
2 ITAC mucinous - - +++
3 ITAC mucinous - - +++
4 ITAC colonic - + +++
5 ITAC mixed (solid and colonic) - ++ -/++
6 ITAC mucinous - + +++
7* ITAC mucinous - - +++
8 ITAC mucinous - - +++
9 ITAC mixed (papillary and mucinous) - +++ +++
10** non ITAC high-grade - - -
11 non ITAC high-grade +++ ++ -
12 ITAC papillary - +++ +++
13 ITAC mucinous - - +++
14 ITAC papillary - - +++
15 ITAC mucinous - - +++
16 ITAC mixed (papillary and mucinous) - ++ +++
17 ITAC papillary - ++ +++
18 ITAC mixed (papillary, colonic and mucinous) - + +
19* ITAC mucinous - + +++
20 ITAC mixed (colonic and mucinous) - + +++
21 ITAC mixed (papillary and mucinous) - - +++
22 ITAC papillary - - +++
23 ITAC mixed (papillary and colonic) - - +++
24 ITAC colonic - +++ ++
25 ITAC papillary - + +++
26 ITAC mucinous - - +++
* Patients exposed to leather dust
** No occupational exposure
a- Intensity of immunostaining in tumoral cells:
+++: positivity of 75 to 100% of cells with an strong staining.
++: positivity of 25 to 75% of cells with heterogenous weak to strong staining.
+: focal and weak positivity of 1 to 25% of cells.
-: no staining.Page 9 of 12
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and adenocarcinoma of the small intestine ACS5 expres-
sion is decreased [54] while it is up-regulated in gliomas
[55], in well-differentiated endometrioid adenocarcino-
mas [56] and in certain colorectal adenocarcinomas [57].
The RT-qPCR data in our panel of tumors revealed an
increase in the expression of ACS5 (p = 0.001),
eventhough it has not been confirmed by IHC. Whereas
some tumors expressed strong ACS5, others had com-
pletely lost the expression of this molecule. Moreover, we
could not find any correlation between ACS5 expression
and histological type, differentiation or collateral expo-
sures.
The other selected genes were not evaluated by immuno-
histochemistry as their variation in expression was much
lower and our primary goal was to find new markers for a
better characterization of these tumors with a clear etiol-
ogy. Nevertheless, we confirmed the transcriptional pro-
filing obtained with the microarray by RT-qPCR.
SRI (Sorcin) and CCT5 (chaperonin-containing complexe
peptide 1) are less known genes. Both code for multi-drug
resistance proteins and might be involved in the cell
detoxification [58,59]. These genes were slightly overex-
pressed in our panel of tumors. This trend could be related
to the chemical or particle exposures of the patients. In
fact, SRI has also been identified by Differential Display
analysis as being overexpressed in oral cancer mediated by
tobacco-chewing [60].
Conclusion
In conclusion, our transcriptomic study has enabled us to
identify genes involved in sinonasal adenocarcinomas.
The validation of microarray data by RT-qPCR and immu-
nohistochemistry confirmed the significant alterations of
LGALS4 and CLU expression. Because of the low inci-
dence of these tumors we had a limited number of
patients and only one without wood exposure, preventing
any correlation between survival and wood exposure.
Nevertheless, after validation using tissue microarrays in a
large set of tumors, including pre-cancerous lesions and
early stages, LGALS4 and CLU could be included in a
panel of non invasive diagnostic/prognostic tests for the
follow-up of woodworkers, to allow an earlier detection
of lesions using a sinonasal smear.
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Representative cases of LGALS4, CLU and ACS5 expression in matched normal mucosa (×100), and tumor tissue (×25)Figure 3
Representative cases of LGALS4, CLU and ACS5 
expression in matched normal mucosa (×100), and 
tumor tissue (×25). A-B-C: Normal sinusal mucosa immu-
nostaining. (A-C): Weak and focal cytoplasmic staining of 
serous cells in a few seromucinous glands with LGALS4 and 
CLU. (A):Weak staining of respiratory epithelium with 
LGALS4. (B): Strong and diffuse immunostaining of serous 
cells with ACS5. D-E-F: Tumor immunostaining. (D): Poorly-
differentiated "solid-type" component showing no immunore-
activity for LGALS4 while the "colonic-type" component is 
positive in a mixed ITAC (patient 5). (E): Example of ACS5 
expression in a "colonic-type" ITAC. (F): No immunoreactiv-
ity for CLU in tumor samples (×100) except in one non-
ITAC (Insert * (×25), Patient 11).Page 10 of 12
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